SEC Filing Summary: Prestige Brands Holdings, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) on December 21, 2007. The report details a material definitive agreement entered into by Medtech Products Inc., an indirect wholly-owned subsidiary of the registrant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement rather than financial performance data.
Material Changes
The primary material change reported is the execution of two Contract Manufacturing Agreements with Pharmaspray B.V. on December 21, 2007. These agreements designate Pharmaspray as the exclusive manufacturer for the following brands in specific markets:
- Wartner® (cryogenic wart remover)
- Compound W® Freeze Off® (cryogenic wart remover)
Each contract carries an initial term of three years.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the operational shift to an exclusive third-party manufacturer for the specified products. No unusual items or contingencies were disclosed in this text.
Investor Verification Checklist
- Verify the specific geographic markets designated for Pharmaspray's exclusive manufacturing rights.
- Confirm the financial terms and volume commitments within the three-year contracts.
- Assess the impact of outsourcing cryogenic wart remover production on future cost structures and margins.
- Review subsequent filings for any amendments or terminations of these agreements.